secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001808805-25-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY
------------------------------------------------------------

- Net loss $16.6M, improved from $18.7M in Q1 2024.
- Operating expenses $18.8M, down 13% from $21.6M prior year.
- Cash, equivalents, and investments $192.8M as of March 31, 2025.
- CEO reports progress on Tau proteoform assay toward commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000039/0001808805-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000039/naut-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001808805-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer